UTRF licenses cell line commercial rights to CytoSen Therapeutics
The University of Tennessee’s Research Foundation recently executed a license granting CytoSen Therapeutics Inc. the commercial rights to use the K-562 cell lines to produce an innovative natural killer cell therapy that harnesses the power of a person’s own immune cells to help fight cancer. Read more here.
Like what you've read?
Forward to a friend!